EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Experimental Study of YaJieShaBa Antialcoholic Hepatic Fibrosis Through TGF‐β1/Smad Signaling Pathway

Linao Zhang iD, Yuanmei Bai iD, Shifang Luo, Feifan Liu, Lijie Zheng, Yan Wan, Xue Wu, Qinghua Chen iD, Yuhuan Xie iD, Peixin Guo iD

Mediators of Inflammation · 2026-01 · 2026 (1)

DOI: 10.1155/mi/2319470 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Mediators of Inflammation, online erschienen am 12.06.2026. Verfasst von Linao Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: College of Chinese Medicine, Yunnan University of Chinese Medicine, Kunming, Yunnan, China, ynutcm.edu.cn. Hauptthemen laut MEDLINE: Transforming Growth Factor beta1, Smad Proteins, Liver Cirrhosis, Alcoholic. Die Arbeit nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, National Natural Science Foundation of China, National Administration of Traditional Chinese Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aimed to clarify the pharmacodynamic effects of YaJieShaBa (YJSB) against alcoholic hepatic fibrosis (HF) and elucidate its mechanism in regulating the transforming growth factor‐β1 (TGF‐β1)/Smad pathway.

Methods

Induce the alcoholic HF model in rats using 56% ethanol (10 mL/kg). The pharmacological efficacy of YJSB in combating liver fibrosis was evaluated through comprehensive assessments of key indicators: body weight, liver mass and index, biochemical liver function parameters (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]), liver fibrosis biomarkers (type Ⅲ procollagen amino‐terminal propeptide [PⅢNP], type‐Ⅳ collagen (COL‐Ⅳ), laminin (LN), and hyaluronic acid [HA]), serum hydroxyproline (Hyp) and TGF‐β1 levels, hepatocyte homogenate levels of COL‐I, COL‐Ⅲ, and α‐smooth muscle actin (α‐SMA), along with histopathological changes observed in liver tissue via hematoxylin and eosin (H&E) staining, Ag staining, and Masson staining. Pathway‐focused qPCR array analysis was used to detect the expression of 72 genes related to signaling pathways such as TGF‐β1, Keap1‐Nrf2, and TLR4/MyD88 in liver tissue from the control group, model group, and YJSB group, identifying differentially expressed genes (DEGs) and key signaling pathways between the model group and the YJSB treatment group. Finally, based on the results of the pathway‐focused qPCR array, the mechanism of action of YJSB against HF was validated using ELISA, WB, and immunofluorescence methods. Concurrently, TGF‐β1 receptor inhibitors were employed in vitro experiments to determine whether YJSB could still provide additional protective effects when the TGF‐β1/Smad pathway was maximally blocked. Furthermore, after confirming that YJSB could inhibit TGF‐β1‐induced activation, a rescue experiment was conducted by adding exogenous TGF‐β1 to observe whether it could reverse the inhibitory effects of YJSB.

Results

YJSB administration significantly increased body mass and decreased liver index in alcoholic HF rats. Serum levels of AST, ALT, PⅢNP, COL‐Ⅳ, LN, HA, Hyp, and TGF‐β1 were significantly reduced, as were the levels of COL‐I, Ⅲ, and α‐SMA in liver homogenates. Histological analyses, including H&E, Ag, and Masson staining, revealed a significant reduction in liver damage. Pathway‐focused qPCR array results showed that, compared with the blank group, 65 genes were upregulated and seven genes were downregulated in the model group, among which the relative expression levels of 40 genes were statistically significant (expression change factor ≥ 1 and p < 0.05). Compared with the model group, 68 genes were downregulated, and four genes were upregulated in the YJSB group, with 34 genes showing statistically significant relative expression levels (fold change [FC] ≥ 2 and p < 0.05). The DEGs were primarily enriched in the TGF‐β1 signaling pathway. Additionally, YJSB reduced the levels of inflammatory factors IL‐1β, TNF‐α, IL‐6, and IL‐8 in liver tissue homogenates while increasing SOD, GSH‐Px, and catalase (CAT) levels and decreasing MDA and ROS levels. Western blotting results showed that YJSB downregulated the expression levels of TGF‐β1, Smad2, Smad3, P‐Smad2, and P‐Smad3 in the liver. Immunofluorescence results indicated that YJSB downregulated the expression levels of Smad4 in hepatocyte nuclei. In vitro experiments demonstrated that the mechanism of YJSB involves primarily inhibiting TGF‐βR1 receptor activation, effectively downregulating P‐Smad2/3 protein levels, as validated by the TGF‐βR1 inhibitor LY2157299. Concurrently, in rescue experiments, the inhibitory effect of YJSB on P‐Smad2/3 protein was partially reversed by exogenous TGF‐β1, indicating that YJSB’s antifibrotic action is highly correlated with the TGF‐β1/Smad pathway.

Conclusion

YJSB effectively inhibits the inflammatory and oxidative stress–related cascade by regulating the TGF‐β1/Smad signaling pathway (TSSP), thus suppressing the progression of alcoholic HF. This demonstrates that YJSB possesses potential for combating alcoholic HF in animal models, providing experimental evidence for its subsequent research and clinical application.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transforming Growth Factor beta1Smad ProteinsLiver Cirrhosis, AlcoholicAnimalsSignal TransductionRatsMaleLiverRats, Sprague-Dawley

Stichwörter der Autor:innen

TGF-β1/Smad pathwayalcoholic hepatic fibrosismechanismspathway-focused qPCR arraypharmacodynamics

Substanzen

Transforming Growth Factor beta1Smad Proteins

Autor:innen und Institutionen

  • College of Chinese Medicine, Yunnan University of Chinese Medicine, Kunming, Yunnan, China, ynutcm.edu.cn.
  • Yunnan Key Laboratory of Dai and Yi Medicines, Yunnan University of Chinese Medicine, Kunming, Yunnan, China, ynutcm.edu.cn.
  • State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China, scu.edu.cn.
  • College of Ethnic Medicine, Yunnan University of Chinese Medicine, Kunming, Yunnan, China, ynutcm.edu.cn.
  • College of Basic Medical Sciences, Yunnan University of Chinese Medicine, Kunming, Yunnan, China, ynutcm.edu.cn.
  • School of Medicine, Yunnan College of Business Management, Kunming, Yunnan, China, ynjgy.com.

ORCID-Profile: Linao Zhang, Yuanmei Bai, Qinghua Chen, Yuhuan Xie, Peixin Guo

Förderung

  • NIA NIH HHS
  • National Natural Science Foundation of China
  • National Administration of Traditional Chinese Medicine
  • Open Research Fund Program of Yunnan Key Laboratory
  • Yunnan Key Laboratory of Formulated Granules

Zitieren

APA

Zhang, L., Bai, Y., Luo, S., Liu, F., Zheng, L., Wan, Y., Wu, X., Chen, Q., Xie, Y., & Guo, P. (2026). Experimental Study of YaJieShaBa Antialcoholic Hepatic Fibrosis Through TGF‐β1/Smad Signaling Pathway. Mediators of Inflammation, 2026(1). https://doi.org/10.1155/mi/2319470

Vancouver

Zhang L, Bai Y, Luo S, Liu F, Zheng L, Wan Y, et al. Experimental Study of YaJieShaBa Antialcoholic Hepatic Fibrosis Through TGF‐β1/Smad Signaling Pathway. Mediators of Inflammation. 2026;2026(1). doi:10.1155/mi/2319470

BibTeX
@article{Zhang2026,
  author = {Zhang, Linao and Bai, Yuanmei and Luo, Shifang and Liu, Feifan and Zheng, Lijie and Wan, Yan and Wu, Xue and Chen, Qinghua and Xie, Yuhuan and Guo, Peixin},
  title = {Experimental Study of YaJieShaBa Antialcoholic Hepatic Fibrosis Through TGF‐β1/Smad Signaling Pathway},
  journal = {Mediators of Inflammation},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/mi/2319470}
}
Kostenlos starten →